Quarterly report [Sections 13 or 15(d)]

In-licensing and Acquisition - Narrative (Details)

v3.26.1
In-licensing and Acquisition - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 22, 2024
Jul. 31, 2024
Dec. 31, 2022
Jul. 31, 2022
Mar. 31, 2026
Dec. 31, 2022
Dec. 31, 2025
Asset Acquisition [Line Items]              
Acquisition-related liabilities         $ 5,000   $ 5,000 [1]
Accounts payable         $ 4,486   7,191 [1]
Forma              
Asset Acquisition [Line Items]              
Upfront fee       $ 2,000      
Research and development           $ 2,000  
Forma | Commercial milestones              
Asset Acquisition [Line Items]              
Potential payments       165,500      
Forma | Development and regulatory milestones              
Asset Acquisition [Line Items]              
Potential payments       $ 67,500      
Forma | Achievement of certain near-term regulatory milestone              
Asset Acquisition [Line Items]              
Research and development     $ 2,500        
GAVRETO (pralsetinib)              
Asset Acquisition [Line Items]              
Estimated useful life         12 years    
REZLIDHIA              
Asset Acquisition [Line Items]              
Estimated useful life         14 years    
REZLIDHIA | FDA approval and first commercial sale of product              
Asset Acquisition [Line Items]              
Accounts payable     $ 15,000     $ 15,000  
Blueprint | GAVRETO (pralsetinib)              
Asset Acquisition [Line Items]              
Asset acquisition, expected price $ 15,000            
Purchase consideration 15,400            
Acquisition payment 15,000 $ 10,000          
Transaction costs $ 400            
Acquisition-related liabilities         $ 5,000   $ 5,000
Blueprint | GAVRETO (pralsetinib) | Minimum [Member]              
Asset Acquisition [Line Items]              
Potential tiered royalties 10.00%            
Blueprint | GAVRETO (pralsetinib) | Maximum [Member]              
Asset Acquisition [Line Items]              
Potential tiered royalties 30.00%            
Blueprint | GAVRETO (pralsetinib) | First commercial sale              
Asset Acquisition [Line Items]              
Asset acquisition, expected price $ 10,000            
Blueprint | GAVRETO (pralsetinib) | First anniversary of the closing date              
Asset Acquisition [Line Items]              
Asset acquisition, expected price 5,000            
Blueprint | GAVRETO (pralsetinib) | Commercial milestones              
Asset Acquisition [Line Items]              
Potential milestone payments 97,500            
Blueprint | GAVRETO (pralsetinib) | Regulatory milestones              
Asset Acquisition [Line Items]              
Potential milestone payments $ 5,000            
[1] The balance sheet as of December 31, 2025 has been derived from the audited financial statements included in Rigel’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 3, 2026.